• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Tell me about the Bone Health Unit









Looking for any and all info regarding the Bone Health unit. Looking at a opportunity in my area.
Recent management structure change and bone now encompasses the salesforce that sells Aimovig for migraine as well. Historically this has been a precursor to structure changes for us in the field. Likely to announce restructure in Q1 '23 at the latest. Possibly sooner. This has been the pattern that we've followed for the last 12 years.
Both bone products have about three years left on patent without much of a game plan for the future other than to cost cut and price cut in an effort to compete with bio-sims.
Not a bad play to jump in and get buy and bill experience and then move on. This is not a position with good long term prospects though.